Dengue

Infectious Disease·MeSH: Dengue

Prevalence

5.0 / 100K

8 drugs in development·7 companies·3 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
BinaxNOW® / Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)

Phase 3(3)

Drug	Company
n-acetylcysteine	GH Research PLC (GHRS)
tdv	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tdv	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(2)

Drug	Company
eyu688	NOVARTIS AG (NVSEF)
eyu688	Novartis AG (NVS)

Unknown(2)

Drug	Company
BinaxNOW® and Panbio® rapid testing platforms	ABBOTT LABORATORIES (ABT)
dengue tetravalent vaccine	Sanofi (SNY)

BioSniper tracks 8 drugs in development for Dengue across 7 companies.

There are 3 clinical trials targeting Dengue tracked by BioSniper.

The estimated prevalence of Dengue is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.